Novel orally active, dibenzazepinone-based γ-secretase inhibitors

Structural modifications of the gamma-secretase inhibitor, LY411575, led to a malonamide analogue (S),(S)-1 with potent inhibitory activity in vitro, but disappointing activity in a mouse model of Alzheimer's disease. Identification and replacement of a metabolically labile position provided an improved compound (R/S),(S)-13 with high in vitro activity (IC(50)=1.7 nM), and in vivo activity after oral administration (MED=3 mg/kg). Further modifications gave an equipotent carbamate analogue 14 with improved molecular properties.

[1]  T. Shepherd,et al.  Progress toward the discovery and development of efficacious BACE inhibitors. , 2006, Current opinion in drug discovery & development.

[2]  I. Churcher,et al.  γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease , 2005 .

[3]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[4]  A. Nadin,et al.  Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide] , 2005, Journal of Pharmacology and Experimental Therapeutics.

[5]  M. Wolfe,et al.  Chapter 5. Secretase inhibitors for Alzheimer's disease , 2003 .

[6]  Michael G. Yang,et al.  Design and synthesis of benzoazepinone-derived cyclic malonamides and aminoamides as potent γ-secretase inhibitors , 2007 .

[7]  Min Xu,et al.  Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Heinrikson,et al.  Human β-Secretase (BACE) and BACE Inhibitors , 2003 .

[9]  J. Kemp,et al.  PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation , 2003, The Journal of Neuroscience.

[10]  G. Keating,et al.  Management of Mild to Moderate Alzheimer Disease , 2004 .

[11]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[12]  D. Selkoe,et al.  Alzheimer disease: mechanistic understanding predicts novel therapies. , 2004 .

[13]  S. Röhrig,et al.  Caspase‐mediated cleavage is not required for the activity of presenilins in amyloidogenesis and NOTCH signaling , 1998, Neuroreport.

[14]  Jay S. Fine,et al.  Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.

[15]  T. Lanz,et al.  Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  Clifford J. Woolf,et al.  Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management , 2004, Annals of Internal Medicine.

[17]  Marcela Colombres,et al.  Structure and function of amyloid in Alzheimer's disease , 2004, Progress in Neurobiology.

[18]  M. Kansy,et al.  Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists. , 2004, Drug discovery today. Technologies.

[19]  D. Selkoe,et al.  Defining molecular targets to prevent Alzheimer disease. , 2005, Archives of neurology.

[20]  D. Ewbank.  Deaths attributable to Alzheimer's disease in the United States. , 1999, American journal of public health.

[21]  H. Josien.  Recent advances in the development of gamma-secretase inhibitors. , 2002, Current opinion in drug discovery & development.